Navigation Links
Study IDs Protein That Inhibits HIV From Growing In Cell Cultures

How a harmless virus called GB Virus type C (GBV-C) protects against HIV infection is now better understood. Researchers at the Department of Veterans Affairs (VA) Iowa// City Health Care System and the University of Iowa have identified a protein segment that strongly inhibits HIV from growing in cell models.

The team found that an 85-amino acid segment within a GBV-C viral protein called NS5A greatly slows down HIV from replicating in cells grown in labs. The study results will appear online this week in the Proceedings of the National Academy of Sciences.

The finding builds on earlier VA and UI work showing that people with HIV who also are infected GBV-C live longer than those infected only with HIV, said Jinhua Xiang, M.D., a VA research health scientific specialist, UI researcher and the current study's principal author.

GBV-C and its role in HIV infection have been studied for nearly a decade by Xiang, along with another study author Jack Stapleton, M.D., staff physician and researcher at the VA Iowa City Health Care System and professor of internal medicine at the UI Roy J. and Lucille A. Carver College of Medicine.

"Identifying a specific protein made by GBV-C that inhibits HIV growth in cell culture strengthens the argument that GBV-C is responsible for the prolonged survival observed in several studies of HIV-positive people," Xiang said. "Understanding how the protein works may allow us to develop target-specific therapies that can mimic these effects and inhibit HIV.

"Potentially these novel therapies would have certain advantages over current drugs, as the newer therapies would target the cell in which HIV can replicate and not the virus directly. Therefore, HIV should have more difficulty developing resistance to the effects of this protein," Xiang added.

Xiang previously discovered that GBV-C grows in the same type of white blood cells, CD4 T-cells, that HIV grows in and ultimate ly destroys. HIV attaches to this T-cell by first landing on a receptor called CD4. Once it reacts with the receptor, HIV can enter the cell, multiply and destroy the T-cell, thereby causing immune deficiency.

"People with GBV-C have a slower rate of destruction of these T-cells," said Stapleton, who also is director of the Division of Infectious Diseases at the Iowa City VA and UI.

The current study shows that the newly identified protein, NS5A, inhibits HIV in part by decreasing the number of CD4 receptors available to HIV. With fewer places for HIV to "dock," less HIV enters the cells to inflict destruction.

However, Xiang cautioned, this is only part of the story, and the researchers must continue work to understand how the NS5A protein exerts its total effect.

"Before NS5A can be used for any kind of therapy, we need to further map it," Xiang said. "We need to zero in to see what region has the critical effect on HIV inhibition."

Once that is accomplished, the team will seek to develop small molecular drugs that mimic the inhibiting action.

Stapleton noted that GBV-C is not toxic to T-cells and is not associated with any human disease. As a result, the U.S. Food and Drug Administration does not require that blood donations be screened for this common virus.

Up to 3 percent of healthy blood donors in the United States have active GBV-C infection. An additional 12 percent have antibodies indicating past exposure at the time of donation. Because the GBV-virus is transmitted through bodily fluids, as is HIV, many HIV-positive individuals have evidence of past or present infection with GBV-C.

Stapleton and Xiang first began studying the GBV-C and HIV connection because they were skeptical of earlier studies published in the mid-1990s.

"It was a strange story," Stapleton said. "Who would have thought a virus floating around in a lot of people does not make them sick but could significantly influence survival in people with HIV?"

Source-Newswise
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
Breaking Medicine Technology: